Analysis of interleukin-10 promoter single nucleotide polymorphisms and risk of non-Hodgkin lymphoma in a Malaysian population

Abstract We evaluated the association of two IL10 single nucleotide polymorphisms (SNPs) (rs1800896 and rs1800871) with non-Hodgkin lymphoma (NHL) risk in the three major races of the Malaysian population (Malay, Chinese and Indian; 317 cases and 330 controls). Our initial screening demonstrated that rs1800871 but not rs1800896 was significantly associated with increased NHL risk in Malays (pMalay-Rec = 0.007) and Chinese only (pChinese-Rec = 0.039). Subsequent combined analysis of the Malay and Chinese revealed significant association of rs1800871 with all (ALL) NHL subtypes (pMeta-ALL-NHL-Rec = 0.001), ALL B-cell subtypes (pMeta-ALL-B-cell-Rec = 0.003), diffuse large B-cell lymphoma (DLBCL) subtype (pMeta-DLBCL-Rec = 0.002) and ALL T-cell subtypes (pMeta-ALL-T-cell-Rec = 0.031). SNP rs1800896 showed increased risk only in follicular lymphoma (FL) (pMeta-FL-Dom = 0.0004). We also detected a male-specific association of rs1800871 with increased NHL risk (pMeta-Male-ALL-NHL-Rec = 0.006) in the combined analysis. To our knowledge, this is the first report on the association of IL10 promoter SNPs with NHL susceptibility in the three major races of Malaysia.

[1]  N. Rothman,et al.  IL10 and TNF variants and risk of non-Hodgkin lymphoma among three Asian populations , 2013, International Journal of Hematology.

[2]  P. Zou,et al.  Genetic association of interleukin-10 promoter polymorphisms and susceptibility to diffuse large B-cell lymphoma: a meta-analysis. , 2013, Gene.

[3]  R. Hassan,et al.  Relationship of Epstein-Barr Virus and Interleukin 10 Promoter Polymorphisms with the Risk and Clinical Outcome of Childhood Burkitt Lymphoma , 2012, PloS one.

[4]  T. Witzig,et al.  Elevated serum IL-10 levels in diffuse large B-cell lymphoma: a mechanism of aberrant JAK2 activation. , 2012, Blood.

[5]  R. Gascoyne,et al.  MYC and Aggressive B-cell Lymphomas , 2011, Advances in anatomic pathology.

[6]  J. Margolick,et al.  Cytokine signaling pathway polymorphisms and AIDS-related non-Hodgkin lymphoma risk in the multicenter AIDS cohort study , 2010, AIDS.

[7]  Yunbo Sun,et al.  Association of interleukin-10 gene polymorphism with cachexia in Chinese patients with gastric cancer. , 2010, Annals of clinical and laboratory science.

[8]  Margarida Saraiva,et al.  The regulation of IL-10 production by immune cells , 2010, Nature Reviews Immunology.

[9]  L. Zeng,et al.  Clinical relevance of the interleukin 10 promoter polymorphisms in Chinese Han patients with major trauma: genetic association studies , 2009, Critical care.

[10]  L. Castellano,et al.  Immunological and Genetic Evidence for a Crucial Role of IL-10 in Cutaneous Lesions in Humans Infected with Leishmania braziliensis1 , 2008, The Journal of Immunology.

[11]  M. Shaw,et al.  A review of the association between antipsychotic use and hyperprolactinaemia , 2008, Journal of psychopharmacology.

[12]  K. Kuliczkowski,et al.  Interleukin-10 gene polymorphisms influence the clinical course of non-Hodgkin's lymphoma. , 2008, Tissue antigens.

[13]  Manuel A. R. Ferreira,et al.  PLINK: a tool set for whole-genome association and population-based linkage analyses. , 2007, American journal of human genetics.

[14]  Yeon-Hee Park,et al.  Interleukin‐10 gene polymorphism influences the prognosis of T‐cell non‐Hodgkin lymphomas , 2007, British journal of haematology.

[15]  George C. Klein An Investigation , 2007 .

[16]  N. Rothman,et al.  Polymorphisms in immune function genes and risk of non-Hodgkin lymphoma: findings from the New South Wales non-Hodgkin Lymphoma Study. , 2007, Carcinogenesis.

[17]  Peter Boyle,et al.  Cytokine polymorphisms in the Th1/Th2 pathway and susceptibility to non-Hodgkin lymphoma. , 2006, Blood.

[18]  R. Houot,et al.  Elevated IL-10 plasma levels correlate with poor prognosis in diffuse large B-cell lymphoma. , 2006, European cytokine network.

[19]  F. Marincola,et al.  Interleukin‐10 and the immune response against cancer: a counterpoint , 2005, Journal of leukocyte biology.

[20]  Weiping Zou,et al.  Immunosuppressive networks in the tumour environment and their therapeutic relevance , 2005, Nature Reviews Cancer.

[21]  H. Baz,et al.  Serum IL-10 and IL-6 levels at diagnosis as independent predictors of outcome in non-Hodgkin’s lymphoma , 2004, Journal of Physiology and Biochemistry.

[22]  G. Salles,et al.  Interleukin-10 gene promoter polymorphisms influence the clinical outcome of diffuse large B-cell lymphoma. , 2004, Blood.

[23]  G. Marti,et al.  Studies in NZB IL-10 knockout mice of the requirement of IL-10 for progression of B-cell lymphoma , 2004, Leukemia.

[24]  S. O’Brien,et al.  Non-Hodgkin's B cell lymphoma in persons with acquired immunodeficiency syndrome is associated with increased serum levels of IL10, or the IL10 promoter -592 C/C genotype. , 2003, Clinical immunology.

[25]  P. Costeas,et al.  Cytokine polymorphism frequencies in the Greek Cypriot population. , 2003, European journal of immunogenetics : official journal of the British Society for Histocompatibility and Immunogenetics.

[26]  Randy D Gascoyne,et al.  Non-Hodgkin lymphoma , 2016, Medicine.

[27]  B. Hancock,et al.  Non-Hodgkin lymphoma , 2003, The Lancet.

[28]  T. Ottenhoff,et al.  Interleukin–10 promoter haplotypes are differently distributed in the Brazilian versus the Dutch population , 2003, Immunogenetics.

[29]  Peter Lipsky,et al.  Cytokines and their role in lymphoid development, differentiation and homeostasis , 2002, Current opinion in allergy and clinical immunology.

[30]  R. Fimmers,et al.  Differential regulation of interleukin-10 production by genetic and environmental factors – a twin study , 2002, Genes and Immunity.

[31]  M. Hammond,et al.  Frequency of cytokine polymorphisms in populations from western Europe, Africa, Asia, the Middle East and South America. , 2002, Human immunology.

[32]  D. Harlan,et al.  Ethnicity Greatly Influences Cytokine Gene Polymorphism Distribution , 2002, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[33]  A. Syvänen Accessing genetic variation: genotyping single nucleotide polymorphisms , 2001, Nature Reviews Genetics.

[34]  S. Ye,et al.  Note: A MnlI Restriction Site Polymorphism in the Interleukin-10 Gene Promoter , 2001, Biochemical Genetics.

[35]  L. Padyukov,et al.  Different allelic frequencies of several cytokine genes in Hong Kong Chinese and Swedish Caucasians , 2001, Genes and Immunity.

[36]  R. Westendorp,et al.  Novel Single Nucleotide Polymorphisms in the Distal IL-10 Promoter Affect IL-10 Production and Enhance the Risk of Systemic Lupus Erythematosus1 , 2001, The Journal of Immunology.

[37]  B. Bonavida,et al.  Inhibition of interleukin 10 by rituximab results in down-regulation of bcl-2 and sensitization of B-cell non-Hodgkin's lymphoma to apoptosis. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[38]  K. Weiss,et al.  How many diseases does it take to map a gene with SNPs? , 2000, Nature Genetics.

[39]  H. Granger,et al.  Abolished angiogenicity and tumorigenicity of Burkitt lymphoma by interleukin-10. , 2000, Blood.

[40]  T. Huizinga,et al.  Microsatellite alleles and single nucleotide polymorphisms (SNP) combine to form four major haplotype families at the human interleukin-10 (IL-10) locus , 1999, Genes and Immunity.

[41]  L. Klareskog,et al.  Increased number of interleukin-10-producing cells in systemic lupus erythematosus patients and their first-degree relatives and spouses in Icelandic multicase families. , 1999, Arthritis and rheumatism.

[42]  P. Woo,et al.  Polymorphic haplotypes of the interleukin-10 5' flanking region determine variable interleukin-10 transcription and are associated with particular phenotypes of juvenile rheumatoid arthritis. , 1999, Arthritis and rheumatism.

[43]  M. Caligiuri,et al.  A review of the association between interleukin-10 and human B-cell malignancies , 1998, Cancer Immunology, Immunotherapy.

[44]  J. Lanchbury,et al.  Interleukin-10 promoter polymorphisms in Southern Chinese patients with systemic lupus erythematosus. , 1998, Arthritis and rheumatism.

[45]  M. Feldmann,et al.  Interleukin‐10 rescues T cells from apoptotic cell death: association with an upregulation of Bcl‐2 , 1997, Immunology.

[46]  M. Lazarus,et al.  An investigation of polymorphism in the interleukin-10 gene promoter. , 1997, European journal of immunogenetics : official journal of the British Society for Histocompatibility and Immunogenetics.

[47]  D. Boomsma,et al.  Genetic influence on cytokine production and fatal meningococcal disease , 1997, The Lancet.

[48]  J. Blay,et al.  Interleukin (IL)-10 and IL-6 are produced in vivo by non-Hodgkin's lymphoma cells and act as cooperative growth factors. , 1996, Cancer research.

[49]  P. Galieni,et al.  Prognostic value of serum IL‐10 and soluble IL‐2 receptor levels in aggressive non‐Hodgkin's lymphoma , 1994, British journal of haematology.

[50]  J. Blay,et al.  Serum interleukin-10 in non-Hodgkin's lymphoma: a prognostic factor. , 1993, Blood.

[51]  J. Banchereau,et al.  Interleukin 10 is a potent growth and differentiation factor for activated human B lymphocytes. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[52]  T. Mosmann,et al.  IL-10, a novel growth cofactor for mature and immature T cells. , 1990, Journal of immunology.

[53]  T. Mosmann,et al.  Interleukin 10, a novel B cell stimulatory factor: unresponsiveness of X chromosome-linked immunodeficiency B cells , 1990, The Journal of experimental medicine.

[54]  Gerome Breen,et al.  Genetic Variation , 2020, Population Genetics with R.

[55]  J. Touraine,et al.  Immunosuppressive networks in the tumour environment and their effect in dendritic cells. , 2009, Biochimica et biophysica acta.

[56]  稲垣 淳 Clinical significance of serum Th1-, Th2- and regulatory T cells-associated cytokines in adult T-cell leukemia/lymphoma : high interleukin-5 and -10 levels are significant unfavorable prognostic factors , 2007 .

[57]  Theodore R Holford,et al.  Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: a report from the InterLymph Consortium. , 2006, The Lancet. Oncology.

[58]  M. Rose-Zerilli,et al.  Interleukin-10 Polymorphisms, Cancer Susceptibility and Prognosis , 2005, Familial Cancer.

[59]  R. Mertelsmann,et al.  Epidemiology of non-Hodgkin’s lymphoma (NHL): trends, geographic distribution, and etiology , 2004, Annals of Hematology.

[60]  Y. Lévy,et al.  Interleukin-10 prevents spontaneous death of germinal center B cells by induction of the bcl-2 protein. , 1994, The Journal of clinical investigation.

[61]  Christopher L. Claggett The investigation. , 1978, Hospital supervisor's bulletin.